Galapagos NV
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
04 dec 2013 - 07:30
Statutaire naam
Galapagos NV
Titel
Galapagos reports positive Phase 1 results for GLPG1205
Bericht
Mechelen, Belgium; 4 December 2013 - Galapagos NV (Euronext: GLPG) announced today that GLPG1205, a first-in-class molecule for inflammatory disorders, has demonstrated target engagement, a good safety profile, and favorable drug properties in a Phase 1 study. Galapagos is developing GLPG1205 within its alliance with Janssen Pharmaceutica NV.
Datum laatste update: 27 juli 2024